An overview on immunogenic cell death in cancer biology and therapy

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributormailto:mosarcr@gmail.com-
Autor(es): dc.contributormailto:joseavmorais@gmail.com-
Autor(es): dc.contributormailto:rayaneganassin@hotmail.com-
Autor(es): dc.contributormailto:giulia_rosa12@hotmail.com-
Autor(es): dc.contributormailto:fchagas16@gmail.com-
Autor(es): dc.contributormailto:amandaalencarcabral@gmail.com-
Autor(es): dc.contributormailto:pandolfo.ariane@gmail.com-
Autor(es): dc.contributormailto:victor@spctm.com-
Autor(es): dc.contributormailto:jplongo82@gmail.com-
Autor(es): dc.contributormailto:luisalex@unb.br-
Autor(es): dc.creatorRodrigues, Mosar Corrêa-
Autor(es): dc.creatorMorais, José Athayde Vasconcelos-
Autor(es): dc.creatorGanassin, Rayane-
Autor(es): dc.creatorOliveira, Giulia Rosa Tavares-
Autor(es): dc.creatorCosta, Fabiana Chagas-
Autor(es): dc.creatorMorais, Amanda Alencar Cabral-
Autor(es): dc.creatorSilveira, Ariane Pandolfo-
Autor(es): dc.creatorSilva, Victor Carlos Mello-
Autor(es): dc.creatorLongo, João Paulo Figueiró-
Autor(es): dc.creatorMuehlmann, Luis Alexandre-
Data de aceite: dc.date.accessioned2024-07-22T13:05:59Z-
Data de disponibilização: dc.date.available2024-07-22T13:05:59Z-
Data de envio: dc.date.issued2022-09-23-
Data de envio: dc.date.issued2022-09-23-
Data de envio: dc.date.issued2022-07-27-
Fonte completa do material: dc.identifierhttps://repositorio.unb.br/handle/10482/44883-
Fonte completa do material: dc.identifierhttps://doi.org/10.3390/pharmaceutics14081564-
Fonte completa do material: dc.identifierhttps://orcid.org/0000-0003-3067-4842-
Fonte completa do material: dc.identifierhttps://orcid.org/0000-0002-6974-0889-
Fonte completa do material: dc.identifierhttps://orcid.org/0000-0002-5154-7263-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/817833-
Descrição: dc.descriptionImmunogenic cell death (ICD) is a modality of regulated cell death that is sufficient to promote an adaptive immune response against antigens of the dying cell in an immunocompetent host. An important characteristic of ICD is the release and exposure of damage-associated molecular patterns, which are potent endogenous immune adjuvants. As the induction of ICD can be achieved with conventional cytotoxic agents, it represents a potential approach for the immunotherapy of cancer. Here, different aspects of ICD in cancer biology and treatment are reviewed.-
Formato: dc.formatapplication/pdf-
Publicador: dc.publisherMDPI-
Direitos: dc.rightsAcesso Aberto-
Direitos: dc.rightsPharmaceutics - Articles published in Sustainability will be Open-Access articles distributed under the terms and conditions of the Creative Commons Attribution License (CC BY). The copyright is retained by the author(s). MDPI will insert the following note at the end of the published text: © 2022 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). Fonte: https://www.mdpi.com/journal/pharmaceutics/about. Acesso em: 23 set. 2022.-
Palavras-chave: dc.subjectMorte celular imunogênica-
Palavras-chave: dc.subjectCâncer - tratamento-
Palavras-chave: dc.subjectSistema imunológico-
Título: dc.titleAn overview on immunogenic cell death in cancer biology and therapy-
Aparece nas coleções:Repositório Institucional – UNB

Não existem arquivos associados a este item.